



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0


F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BC09012b : Endometrium cancer tissue array, including pathology grade, TNM and clinical stage, 63 cases/63 cores, replacing BC09012a

Microarray Panel	Endometrium carcinoma tissue microarray, containing 60 cases endometrium carcinoma, plus 3 adjacent normal endometrium tissue, single core per case	
Cores	63	BC09012b H&E 
Cases	63	
Row number	7	
Column number	9	
Core Diameter (mm)	1.5	
Thickness (µm)	5	
Tissue Array Type	FFPE	
Species	Human	
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.	
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, “**” means invalid core; “-” means no applicable or negative in IHC markers.	

	1	2	3	4	5	6	7	8	9
A	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
B	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
C	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
D	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
E	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
F	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
G	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute

Legend: Ute - Uterus

● - Malignant tumor, ● - Malignant tumor, ● - Malignant tumor (stage I), ● - Malignant tumor (stage IA), ● - Malignant tumor (stage IB), ● - Malignant tumor (stage IC), ● - Malignant tumor (stage II), ● - Malignant tumor (stage IIA), ● - Malignant tumor (stage III), ● - Malignant tumor (stage IIIA), ● - Malignant tumor (stage IIIC), ● - NAT

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	54	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
A2	2	55	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
A3	3	40	F	Uterus	Endometrioid adenocarcinoma	T2N0M0	1	II	Malignant	
A4	4	52	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	IC	Malignant	
A5	5	51	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
A6	6	60	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
A7	7	44	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
A8	8	38	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
A9	9	53	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	IC	Malignant	

B1	10	66	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
B2	11	53	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
B3	12	57	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
B4	13	45	F	Uterus	Endometrioid adenocarcinoma	T1aN0M0	1	IA	Malignant	
B5	14	59	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
B6	15	51	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
B7	16	50	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	IC	Malignant	
B8	17	57	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
B9	18	55	F	Uterus	Endometrioid adenocarcinoma	T1aN0M0	1	IIA	Malignant	
C1	19	80	F	Uterus	Endometrioid adenocarcinoma (sparse)	T1bN0M0	1	IB	Malignant	
C2	20	68	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	IC	Malignant	
C3	21	58	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	IC	Malignant	
C4	22	52	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
C5	23	62	F	Uterus	Endometrioid adenocarcinoma	T1N0M0	1	I	Malignant	
C6	24	52	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
C7	25	58	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	IB	Malignant	
C8	26	62	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	IC	Malignant	
C9	27	62	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
D1	28	51	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	IB	Malignant	
D2	29	72	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	IB	Malignant	
D3	30	49	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	IB	Malignant	
D4	31	51	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
D5	32	62	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
D6	33	50	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
D7	34	60	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	IC	Malignant	
D8	35	57	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	IB	Malignant	
D9	36	67	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	IC	Malignant	
E1	37	51	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	IC	Malignant	
E2	38	58	F	Uterus	Endometrioid adenocarcinoma	T1N0M0	2	I	Malignant	
E3	39	62	F	Uterus	Endometrioid adenocarcinoma	T1cN1M0	2	IIIC	Malignant	
E4	40	61	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	IC	Malignant	
E5	41	52	F	Uterus	Adenocarcinoma (sparse)	T1cN0M0	-	IC	Malignant	
E6	42	63	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	IB	Malignant	
E7	43	56	F	Uterus	Endometrioid adenocarcinoma	T1aN0M0	2	IA	Malignant	
E8	44	56	F	Uterus	Endometrioid adenocarcinoma (sparse)	T1bN0M0	1	IB	Malignant	
E9	45	30	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	IC	Malignant	
F1	46	49	F	Uterus	Adenosquamous carcinoma	T1bN0M0	-	IB	Malignant	
F2	47	55	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	3	IB	Malignant	
F3	48	54	F	Uterus	Endometrioid adenocarcinoma	T1N0M0	3	I	Malignant	
F4	49	47	F	Uterus	Endometrioid adenocarcinoma (endometrial tissue)	T1cN0M0	-	IC	Malignant	
F5	50	53	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	IC	Malignant	
F6	51	62	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	IC	Malignant	
F7	52	63	F	Uterus	Endometrioid adenocarcinoma	T1N0M0	3	I	Malignant	
F8	53	48	F	Uterus	Endometrioid adenocarcinoma	T3N0M0	3	III	Malignant	
F9	54	39	F	Uterus	Endometrioid adenocarcinoma (sparse)	T1aN0M0	3	IA	Malignant	
G1	55	78	F	Uterus	Endometrioid adenocarcinoma	T3aN0M0	3	IIIA	Malignant	
G2	56	54	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	IC	Malignant	
G3	57	58	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	3	IB	Malignant	
G4	58	65	F	Uterus	Endometrioid adenocarcinoma with squamous metaplasia	T1bN0M0	3	IB	Malignant	
G5	59	67	F	Uterus	Adenosquamous carcinoma	T2aN0M0	-	IIA	Malignant	
G6	60	38	F	Uterus	Invasive hydatidiform mole with necrosis	-	-	-	Malignant	
G7	61	48	F	Uterus	Adjacent normal endometrium tissue	-	-	-	NAT	
G8	62	52	F	Uterus	Adjacent normal endometrium tissue	-	-	-	NAT	
G9	63	58	F	Uterus	Adjacent normal endometrium tissue	-	-	-	NAT	
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)		-		Malignant	

Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

- Mx - Distant metastasis cannot be assessed
- M0 - No distant metastasis
- M1 - Distant metastasis